Xpert® C. difficile BT
Detection of Clostridioides difficile in Around 45 Minutes
Inicie sessão ou crie uma conta MyCepheid para adicionar itens ao carrinho 
Tamanho(s) da embalagem de teste
product image
10 Testes
GXCDIFFBT-CE-10
Quantidade
Preço unitário
Subtotal
USD
O produto não está disponível para compra na sua região.
Dispositivos de colheita
product image
Collection Device (Pack of 50)
900-0370
Quantidade
Preço unitário
Subtotal
USD
O produto não está disponível para compra na sua região.
product image
Single Use Disposable Swab (Pack of 120)
SDPS-120
Quantidade
Preço unitário
Subtotal
USD
O produto não está disponível para compra na sua região.
Total
{{currency}}
0
Erro ao adicionar itens ao carrinho. Se esse erro persistir, entre em contato com o suporte digital.

The Need

  • Clostridioides difficile (C. difficile) is amongst the most frequently reported micro-organisms in healthcare associated infections in Europe1
  • It is associated with an increase in length of hospital stay, high morbidity and mortality resulting in both societal and financial burden2
  • Highly virulent (027-NAP1-BI) strains have caused outbreaks of severe diseasae in Europe and North America and are often resistant to fluoroquinolones3
  • Although the accurate and rapid diagnosis of C. difficile is essential for effective and timely treatment, this remains an unmet clinical need4
1 Viprey, V. F., Granata, G., & Vendrik, K. (n.d.). European survey on the current surveillance practices, management ... https://www.journalofhospitalinfection.com/article/S0195-6701(22)00365-6/fulltext.
2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051
3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.

The Solution

  • Xpert C. difficile BT provides detection and differentiation of Clostridioides difficile & the epidemic    027 strain, with a callout for binary toxin, in 43 minutes from unformed stool specimens
  • Rapid detection and differentiation of Clostridioides difficile & the epidemic 027 strain optimizes patient management decisions, enables timely and appropriate treatment, and supports infection control and outbreak prevention measures4
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.

The Impact

  • Rapid and accurate detection of toxigenic C. difficile is essential to diagnose CDI to implement optimized therapy and bed management and to help prevent transmission and outbreaks:
    45% reduced empiric therapy5
    48% reduced isolation days6
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).